Nakashima M, Nakano T, Ametani Y, Funamoto H, Uchiyama A, Miwa A, Miyata S, Shoji M, Kondo T, Satake S, Kojima Y
Department of Obstetrics and Gynecology, Toyama Prefectural Central Hospital, 2-2-78 nishinagae Toyama-Shi, Toyama, Japan.
Int J Gynecol Cancer. 2006 May-Jun;16(3):1309-13. doi: 10.1111/j.1525-1438.2006.00455.x.
Prognoses in cases of uterine cervical squamous cell carcinoma treated with radiotherapy were investigated in association with immunohistochemical expression of an angiogenic factor, thymidine phosphorylase (TP). Forty-six cases of uterine cervical squamous cell carcinoma mainly treated with radiotherapy during 1992-2001 at our clinic were studied. All were diagnosed as stages IIB to IVA. Paraffin-embedded biopsy specimens excised before radiotherapy were stained immunohistochemically using anti-TP monoclonal antibody. The extent of staining in both tumor and interstitial cells was graded as (-), (+/-), (+), and (2+). Specimens with TP expression levels of (2+) and (+) were regarded as positively stained and those with TP expression levels of (+/-) and (-) as negatively stained. The efficacy of radiotherapy in both groups was analyzed by the Kaplan-Meier method. With tumor cells, 5-year survival rates for the positive (n= 38) and negative (n= 8) staining groups were 73.9% and 42.9%, respectively; the rate being significantly higher for the TP-positive group (log rank, P= 0.0096). Contrarily, with staining for interstitial cells, the 5-year survival rates for the positive (n= 20) and negative (n= 26) staining groups were 74.1% and 64.6%, respectively, with no significant difference (log rank, P= 0.406). The efficacy of radiotherapy in the group with positive staining of tumor cells was significantly better than in the negative staining group. Immunohistochemical expression of TP in tumor cells is suggested as a useful prognostic factor for uterine cervical squamous cell carcinomas treated with radiotherapy. Choosing therapy for individual cases by referring to factors including TP expression should contribute to an improved prognosis.
结合血管生成因子胸苷磷酸化酶（TP）的免疫组化表达情况，对接受放射治疗的子宫颈鳞状细胞癌病例的预后进行了研究。对1992年至2001年期间在我们诊所主要接受放射治疗的46例子宫颈鳞状细胞癌病例进行了研究。所有病例均诊断为IIB期至IVA期。放疗前切除的石蜡包埋活检标本用抗TP单克隆抗体进行免疫组化染色。肿瘤细胞和间质细胞中的染色程度分为（-）、（+/-）、（+）和（2+）。TP表达水平为（2+）和（+）的标本被视为阳性染色，而TP表达水平为（+/-）和（-）的标本被视为阴性染色。采用Kaplan-Meier法分析两组放疗的疗效。对于肿瘤细胞，阳性染色组（n = 38）和阴性染色组（n = 8）的5年生存率分别为73.9%和42.9%；TP阳性组的生存率显著更高（对数秩检验，P = 0.0096）。相反，对于间质细胞染色，阳性染色组（n = 20）和阴性染色组（n = 26）的5年生存率分别为74.1%和64.6%，无显著差异（对数秩检验，P = 0.406）。肿瘤细胞阳性染色组的放疗疗效明显优于阴性染色组。肿瘤细胞中TP的免疫组化表达被认为是接受放射治疗的子宫颈鳞状细胞癌的一个有用的预后因素。参考包括TP表达在内的因素为个体病例选择治疗方法应有助于改善预后。
